Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Precision medicine and actionable alterations in lung cancer: A single institution experience

PLoS ONE(2020)10.1371/journal.pone.0228188Source: DataRank Database

Precision medicine and actionable alterations in lung cancer: A single institution experience is a research paper published in PLoS ONE (2020). On theSindex it has a DataRank of 0. It has been cited 9 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access9 citations

Free full text

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (6 grants)Impact (FWCI 0.77)OA: goldTopics (77)IDs (PubMed, OpenAlex)SDGs (2)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (24)

Yingyu Wang ORCID,Chen Chen ORCID,Sorena Nadaf,Rebecca Pharaon ORCID,Jeremy Fricke ORCID

Live enrichment

PubMed:32045431 OpenAlex:https://openalex.org/W3006504432

National Cancer Institute

Grant: P30CA033572

National Cancer Institute

Grant: R01CA218545

National Cancer Institute

Grant: U54CA209978

National Institutes of Health

Grant: 5P30CA033572-27

Developmental Funds

National Institutes of Health

Grant: 5U54CA209978-06

Combating Subclonal Evolution of Resistant Cancer Phenotypes

National Institutes of Health

Grant: 5R01CA218545-02

Novel approach to attenuate small cell lung cancer growth and metastasis

FWCI

0.77

Citation Percentile

0.7%

Citation Trend

2020

2021

2022

2023

2024

2025

goldLicense: cc-by

journalhttps://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0228188&type=printable

publisherhttps://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0228188&type=printable

publisherhttps://dx.plos.org/10.1371/journal.pone.0228188

journalhttps://doi.org/10.1371/journal.pone.0228188

repositoryhttps://pubmed.ncbi.nlm.nih.gov/32045431

Fields of Study

Lung Cancer Treatments and MutationsLung Cancer Diagnosis and TreatmentCancer Genomics and Diagnostics03 medical and health sciences0302 clinical medicineAdenocarcinomaAdultAgedAged, 80 and overAnaplastic Lymphoma KinaseErbB ReceptorsFemaleGenetic VariationHumansKaplan-Meier EstimateLung NeoplasmsMaleMiddle AgedPrecision MedicineProportional Hazards ModelsProto-Oncogene Proteins B-rafRegistriesRetrospective StudiesYoung Adult

MeSH Terms

Anaplastic Lymphoma KinaseAdenocarcinomaAdultAgedAged, 80 and overFemaleHumansLung NeoplasmsMaleMiddle AgedRegistriesRetrospective StudiesGenetic VariationProportional Hazards ModelsProto-Oncogene Proteins B-rafKaplan-Meier EstimateYoung AdultPrecision MedicineErbB Receptors

Keywords

Lung cancerMedicinePrecision medicineCancerBioinformaticsIntensive care medicinePathologyBiologyInternal medicineAdultMaleProto-Oncogene Proteins B-rafLung NeoplasmsScienceMedical BiochemistryKaplan-Meier EstimateAdenocarcinomaYoung Adult80 and overHumansAnaplastic Lymphoma KinaseRegistriesAgedProportional Hazards ModelsRetrospective StudiesAged, 80 and overQRGenetic VariationMiddle AgedErbB ReceptorsMedical Molecular BiologyFemaleResearch Article

Sustainable Development Goals

SDG 3: 3. Good healthSDG 0: Industry, innovation and infrastructure